Idorsia confirms 2019 spending plan as drug trials advance


ZURICH, April 18 () - Swiss biotech Idorsia said on Thursday all four trials of its late-stage drug hopefuls were on track as it confirmed expectations of spending 570 million Swiss francs ($564 million) in the current year on its projects.

In the first quarter, Idorsia's net loss widened to 106 million francs, from 79 million in the period in 2018, as it boosted outlays for projects including prospective drugs for insomnia and Fabry disease. The Allschwil-based company had total liquidity of 1.1 billion francs as of March 31, from 1.2 billion at the end of last year.

($1 = 1.0099 Swiss francs)

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics



Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at and via Reuters TV.

Learn More